FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077840948> ?p ?o ?g. }

• W2077840948 endingPage "71" @default.
• W2077840948 startingPage "67" @default.
• W2077840948 abstract "No AccessJournal of UrologyAdult Urology1 Jan 2011Usefulness of the Spanish Urological Club for Oncological Treatment Scoring Model to Predict Nonmuscle Invasive Bladder Cancer Recurrence in Patients Treated With Intravesical Bacillus Calmette-Guérin Plus Interferon-α Henry M. Rosevear, Andrew J. Lightfoot, Kenneth G. Nepple, and Michael A. O'Donnell Henry M. RosevearHenry M. Rosevear More articles by this author , Andrew J. LightfootAndrew J. Lightfoot More articles by this author , Kenneth G. NeppleKenneth G. Nepple More articles by this author , and Michael A. O'DonnellMichael A. O'Donnell Financial interest and/or other relationship with Abbott Laboratories, Alynylam Pharmaceuticals, Viventia, Anadys Pharmaceuticals, Spectrum, Loras, Endo Pharmaceuticals and Medical Enterprises. More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.08.083AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The Spanish Urological Club for Oncological Treatment recently developed a scoring model to stratify the recurrence risk in patients treated with intravesical bacillus Calmette-Guérin using gender, age, grade, tumor status, T category, multiplicity and associated carcinoma in situ. We investigated the ability of this model to stratify the recurrence risk in patients with nonmuscle invasive bladder cancer undergoing combination bacillus Calmette-Guérin plus interferon α-2B therapy. Materials and Methods: We retrospectively reviewed data from a national multicenter phase II trial of bacillus Calmette-Guérin plus interferon α-2B in patients with nonmuscle invasive bladder cancer to identify 718 with the data required to use the model. Recurrence was defined as visible tumor on cystoscopy unless histologically confirmed as benign, definitive positive cytology or biopsy proven disease even with negative cystoscopy. Time to recurrence was indexed to the first intravesical treatment date. Patients were assigned points based on the model and then divided into 4 groups based on total score, including 0 to 4, 5 or 6, 7 to 9 and 10 or greater. Results: The model successfully stratified the recurrence risk into 4 statistically different groups based on score with a 3-year recurrence-free rate of 58%, 52%, 42% and 26% for scores of 0 to 4, 5 or 6, 7 to 9 and 10 or greater, respectively (p <0.001). Conclusions: The Spanish Urological Club for Oncological Treatment scoring model is a useful prognostic tool to stratify recurrence risk in patients with nonmuscle invasive bladder cancer who are treated with combined intravesical bacillus Calmette-Guérin plus interferon α-2B. Larger, prospective trials are required for full model validation. References 1 : EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol2008; 54: 303. Google Scholar 2 : Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol2007; 178: 2314. Link, Google Scholar 3 : Bacillus Calmette-Guerin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Rev Urol2008; 10: 281. Google Scholar 4 : Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol2000; 163: 1124. Link, Google Scholar 5 : Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol2006; 49: 466. Google Scholar 6 : Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol2009; 182: 2195. Link, Google Scholar 7 : Editorial comment: predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated With bacillus Calmette-Guerin: the CUETO scoring model. J Urol2009; 182: 2203. Link, Google Scholar 8 : Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol2006; 24: 344. Google Scholar 9 : Optimizing BCG therapy. Urol Oncol2009; 27: 325. Google Scholar 10 : Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol2002; 167: 364. Link, Google Scholar 11 : The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol2006; 175: 1634. Link, Google Scholar 12 : Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int2002; 89: 671. Google Scholar 13 : BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology (Williston Park)1995; 9: 947. Google Scholar 14 : Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol2000; 163: 1697. Link, Google Scholar 15 : The effect of gender on response to bacillus Calmette-Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU Int2010; 106: 357. Google Scholar 16 Rosevear HM, Lightfoot AJ and O'Donnell MA: Cancer recurrence disparities among racial and gender groups with non-muscle invasive bladder cancer (NMIBC) after intravesical bacillus Calmette-Guerin (BCG) and interferon alpha-2B therapy. Presented at annual meeting of Society for Urologic Oncology, Washington, D.C., December 8–10, 2009. Google Scholar 17 : A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol2004; 171: 2186. Link, Google Scholar 18 : The optimal management of T1 high-grade bladder cancer. Can Urol Assoc J2009; 3: S188. Google Scholar 19 : Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol2000; 163: 60. Link, Google Scholar 20 : The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. BJU Int2009; 103: 475. Google Scholar 21 : Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst2009; 101: 114. Google Scholar 22 : Association of tumour necrosis factor-α gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guerin immunotherapy. BJU Int2009; 104: 867. Google Scholar © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 1January 2011Page: 67-71 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.Keywordsprognosisurinary bladder neoplasmsBCG vaccineurinary bladderinterferon alfa-2bMetricsAuthor Information Henry M. Rosevear More articles by this author Andrew J. Lightfoot More articles by this author Kenneth G. Nepple More articles by this author Michael A. O'Donnell Financial interest and/or other relationship with Abbott Laboratories, Alynylam Pharmaceuticals, Viventia, Anadys Pharmaceuticals, Spectrum, Loras, Endo Pharmaceuticals and Medical Enterprises. More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2077840948 created "2016-06-24" @default.
• W2077840948 creator A5003263712 @default.
• W2077840948 creator A5005817478 @default.
• W2077840948 creator A5053326285 @default.
• W2077840948 creator A5074693628 @default.
• W2077840948 date "2011-01-01" @default.
• W2077840948 modified "2023-10-02" @default.
• W2077840948 title "Usefulness of the Spanish Urological Club for Oncological Treatment Scoring Model to Predict Nonmuscle Invasive Bladder Cancer Recurrence in Patients Treated With Intravesical Bacillus Calmette-Guérin Plus Interferon-α" @default.
• W2077840948 cites W1526426893 @default.
• W2077840948 cites W1578051988 @default.
• W2077840948 cites W1968784805 @default.
• W2077840948 cites W2002045993 @default.
• W2077840948 cites W2004878460 @default.
• W2077840948 cites W2017306423 @default.
• W2077840948 cites W2037602993 @default.
• W2077840948 cites W2051489275 @default.
• W2077840948 cites W2081006498 @default.
• W2077840948 cites W2082941803 @default.
• W2077840948 cites W2086276584 @default.
• W2077840948 cites W2113434837 @default.
• W2077840948 cites W2131778120 @default.
• W2077840948 cites W2152206210 @default.
• W2077840948 cites W2155829623 @default.
• W2077840948 cites W2165543889 @default.
• W2077840948 cites W2166242144 @default.
• W2077840948 cites W4238498110 @default.
• W2077840948 cites W4301656187 @default.
• W2077840948 doi "https://doi.org/10.1016/j.juro.2010.08.083" @default.
• W2077840948 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21074202" @default.
• W2077840948 hasPublicationYear "2011" @default.
• W2077840948 type Work @default.
• W2077840948 sameAs 2077840948 @default.
• W2077840948 citedByCount "22" @default.
• W2077840948 countsByYear W20778409482013 @default.
• W2077840948 countsByYear W20778409482014 @default.
• W2077840948 countsByYear W20778409482015 @default.
• W2077840948 countsByYear W20778409482016 @default.
• W2077840948 countsByYear W20778409482018 @default.
• W2077840948 countsByYear W20778409482021 @default.
• W2077840948 countsByYear W20778409482023 @default.
• W2077840948 crossrefType "journal-article" @default.
• W2077840948 hasAuthorship W2077840948A5003263712 @default.
• W2077840948 hasAuthorship W2077840948A5005817478 @default.
• W2077840948 hasAuthorship W2077840948A5053326285 @default.
• W2077840948 hasAuthorship W2077840948A5074693628 @default.
• W2077840948 hasConcept C121608353 @default.
• W2077840948 hasConcept C126322002 @default.
• W2077840948 hasConcept C126894567 @default.
• W2077840948 hasConcept C143998085 @default.
• W2077840948 hasConcept C2775910329 @default.
• W2077840948 hasConcept C2779150676 @default.
• W2077840948 hasConcept C2780352672 @default.
• W2077840948 hasConcept C54355233 @default.
• W2077840948 hasConcept C71924100 @default.
• W2077840948 hasConcept C86803240 @default.
• W2077840948 hasConceptScore W2077840948C121608353 @default.
• W2077840948 hasConceptScore W2077840948C126322002 @default.
• W2077840948 hasConceptScore W2077840948C126894567 @default.
• W2077840948 hasConceptScore W2077840948C143998085 @default.
• W2077840948 hasConceptScore W2077840948C2775910329 @default.
• W2077840948 hasConceptScore W2077840948C2779150676 @default.
• W2077840948 hasConceptScore W2077840948C2780352672 @default.
• W2077840948 hasConceptScore W2077840948C54355233 @default.
• W2077840948 hasConceptScore W2077840948C71924100 @default.
• W2077840948 hasConceptScore W2077840948C86803240 @default.
• W2077840948 hasIssue "1" @default.
• W2077840948 hasLocation W20778409481 @default.
• W2077840948 hasLocation W20778409482 @default.
• W2077840948 hasOpenAccess W2077840948 @default.
• W2077840948 hasPrimaryLocation W20778409481 @default.
• W2077840948 hasRelatedWork W2078477972 @default.
• W2077840948 hasRelatedWork W2093277251 @default.
• W2077840948 hasRelatedWork W2165762581 @default.
• W2077840948 hasRelatedWork W2790413325 @default.
• W2077840948 hasRelatedWork W2791815030 @default.
• W2077840948 hasRelatedWork W2795614148 @default.
• W2077840948 hasRelatedWork W2903199129 @default.
• W2077840948 hasRelatedWork W3111145153 @default.
• W2077840948 hasRelatedWork W4387207911 @default.
• W2077840948 hasRelatedWork W2118673085 @default.
• W2077840948 hasVolume "185" @default.
• W2077840948 isParatext "false" @default.
• W2077840948 isRetracted "false" @default.
• W2077840948 magId "2077840948" @default.
• W2077840948 workType "article" @default.